Alexis Investment Partners’s Xenetic Biosciences XBIO Stock Holding History

Alexis Investment Partners’s Portfolio XBIO Stock Details XBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-25	Closed	-$54	–	95
2025 Q4	$54	Hold	25	–	–	﹤0.01%	95
2025 Q3	$79	Buy	+25	New	+$82	﹤0.01%	96
2025 Q1	–	Sell	-25	Closed	-$100	–	89
2024 Q4	$100	Buy	+25	New	+$101	﹤0.01%	85

Other funds holding XBIO

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

DWM

Darwin Wealth Management Tampa, Florida $365M AUM 22.69% 1-Year Est. Return

Alexis Investment Partners's XBIO Position: Q1 2026 in Review

Alexis Investment Partners sold out of Xenetic Biosciences (XBIO) in Q1 2026, closing a stake of 25 shares — an estimated $54 sold.

Alexis Investment Partners first reported a position in XBIO in Q4 2024 and held it in 3 quarters. The position peaked at $100 in Q4 2024. 6 funds tracked by Wall St. Rank hold XBIO as of Q1 2026.

Alexis Investment Partners reported no remaining Xenetic Biosciences position as of Q1 2026 after selling out during the quarter.
Alexis Investment Partners sold 25 Xenetic Biosciences shares in Q1 2026, an estimated $54.
Alexis Investment Partners first reported a position in Xenetic Biosciences in Q4 2024 and held it in 3 quarters.
Alexis Investment Partners's Xenetic Biosciences position peaked at $100 in Q4 2024.
6 funds tracked by Wall St. Rank held Xenetic Biosciences as of Q1 2026.

Based on Alexis Investment Partners's 13F filing for Q1 2026, filed 24 Apr 2026.